Stavros derdas | Best Review Article Award | Cancer Biomarker

Published on by Oncology

Best Review Article Award

Stavros derdas
Aegean College

Stavros derdas
Affiliation Aegean College
Country Greece
Scopus ID 6505579887
Documents 17
Citations 487
h-index 9
Subject Area Cancer Biomarker
Event International Research Awards on Oncology and Cancer Research

Stavros derdas is a researcher affiliated with  research activity in the area of cancer biomarkers. The supplied bibliometric record identifies 17 documents, 487 citations, and an h-index of 9 under Scopus Author ID 6505579887. These indicators provide a bibliometric description of the research record and should be interpreted in the context of publication field, document type, citation practices, and database coverage. [1]

Abstract

This academic recognition profile presents STAVROS DERDAS in connection with the Best Review Article Award and the subject area of Cancer Biomarker. The profile is based on the supplied institutional and bibliometric information, including affiliation with AEGEAN COLLEGE, Greece, Scopus Author ID 6505579887, 17 documents, 487 citations, and an h-index of 9. Cancer biomarkers constitute an important research domain within contemporary oncology because biomarkers may support risk assessment, screening, diagnosis, prognosis, treatment-response prediction, and disease monitoring. Their translation into clinical practice requires analytical validation, clinical validation, and assessment of clinical utility. [2] Contemporary research additionally encompasses genomic, transcriptomic, proteomic, circulating, and liquid-biopsy approaches, with continuing emphasis on reproducibility and clinical validation. [3]

Keywords

STAVROS DERDAS; Cancer Biomarker; Cancer Research; Oncology; Biomarker Discovery; Biomarker Validation; Precision Oncology; Diagnostic Biomarkers; Prognostic Biomarkers; Molecular Oncology; Research Review; Academic Research.

Introduction

Cancer biomarker research covers the identification and evaluation of measurable biological characteristics associated with cancer risk, detection, classification, prognosis, treatment response, or disease progression. The field has developed alongside advances in molecular biology, genomics, proteomics, imaging, immunology, and analytical technologies. Reviews of cancer biomarkers emphasize that a candidate biomarker must be evaluated systematically before it can be considered suitable for routine clinical application. [2]

Recent literature describes an expanding biomarker landscape involving conventional protein markers as well as genomic and transcriptomic targets, circulating tumour DNA, circulating tumour cells, microRNAs, and liquid-biopsy technologies. These developments have broadened the possibilities for early detection, molecular characterization, prognosis, treatment selection, and disease monitoring, while also creating requirements for robust validation and reproducibility. [4]

Research Profile

The supplied research profile identifies STAVROS DERDAS with AEGEAN COLLEGE in Greece and associates the researcher with Cancer Biomarker as the principal subject area for this recognition profile. The Scopus information supplied for the profile records 17 documents, 487 citations, and an h-index of 9. Scopus author metrics are database-dependent and can change as publications are indexed, records are corrected, and citations are added. [1]

Research Contributions

The research area represented in this profile is situated within the broader field of cancer biomarker science. Biomarker research can encompass the identification of measurable molecular or biological characteristics, development of analytical assays, assessment of diagnostic or prognostic performance, evaluation of treatment-response indicators, and investigation of biomarkers for disease surveillance. Established literature stresses the distinction between analytical validity, clinical validity, and clinical utility when evaluating candidate biomarkers. [2]

  • Cancer biomarker research connects molecular characteristics with clinically relevant questions involving detection, diagnosis, prognosis, treatment response, and monitoring.
  • Modern biomarker discovery increasingly incorporates genomic, transcriptomic, proteomic, and circulating molecular information. [4]
  • Biomarker development requires appropriate analytical and clinical validation before translation into clinical practice. [2]
  • Emerging detection platforms include liquid biopsy and biosensor-based approaches, which continue to be evaluated for sensitivity, specificity, portability, and clinical applicability. [5]

Publications

The supplied Scopus profile records 17 documents associated with Scopus Author ID 6505579887. The available information does not provide a verified publication-by-publication bibliography for STAVROS DERDAS; therefore, individual publications are not attributed to the researcher in this article without documentary confirmation. The document count is presented as a bibliometric profile indicator rather than as a substitute for a complete publication list. [1]

For contextual purposes, peer-reviewed literature demonstrates the breadth of the cancer biomarker field. Reviews have examined biomarker development, emerging genomic and molecular approaches, biosensor technologies, and the clinical implications of biomarker-guided precision oncology. [2] [3] [5]

Research Impact

The supplied bibliometric record reports 487 citations across 17 documents and an h-index of 9. These figures indicate citation activity associated with the identified Scopus author record, while their interpretation should take into account disciplinary citation patterns, publication types, database coverage, and the timing of indexing. [1]

Within cancer research, biomarker studies can contribute to translational research by providing measurable indicators for biological characterization and clinical decision-making. Contemporary reviews emphasize the continuing movement from conventional protein-based markers toward integrated genomic, transcriptomic, proteomic, and liquid-biopsy approaches. [3] [4] The scientific impact of individual biomarker research ultimately depends on factors such as reproducibility, independent validation, clinical relevance, methodological quality, and successful translation.

Award Suitability

The Best Review Article Award is presented here in relation to the research profile supplied for STAVROS DERDAS, with Cancer Biomarker identified as the relevant subject area. The profile contains bibliometric evidence of scholarly activity, including 17 documents, 487 citations, and an h-index of 9. [1] The suitability of a review-article recognition should additionally be assessed against the specific award’s formal criteria, including the documented review article or articles, originality and synthesis of the literature, methodological rigor, scholarly contribution, relevance to oncology and cancer research, and evidence supporting the submitted work.

The associated event is the International Research Awards on Oncology and Cancer Research. The event website describes the awards as recognizing researchers, scientists, academicians, healthcare professionals, and innovators working across areas including oncology, cancer therapy, precision medicine, immunotherapy, and translational science. [6] The award profile should therefore be understood as an academic recognition page based on the supplied researcher information rather than as an independent assessment of the researcher’s complete scholarly record.

Conclusion

STAVROS DERDAS, affiliated with AEGEAN COLLEGE in Greece, is represented in this profile within the research area of Cancer Biomarker. The supplied Scopus information records 17 documents, 487 citations, and an h-index of 9 under Author ID 6505579887. Cancer biomarker research remains an interdisciplinary area involving molecular discovery, analytical development, clinical validation, and translational oncology. [2] [3] The Best Review Article Award recognition is contextualized by this documented research profile and by the broader relevance of biomarker research to oncology and cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: STAVROS DERDAS, Author ID 6505579887. Scopus.https://www.scopus.com/authid/detail.uri?authorId=6505579887
  2. Henry, N. L., & Hayes, D. F. (2012). Cancer biomarkers. Molecular Oncology, 6(2), 140–146. DOI: 10.1016/j.molonc.2012.01.010.https://doi.org/10.1016/j.molonc.2012.01.010
  3. Passaro, A., et al. (2024). Cancer Biomarkers: Emerging Trends and Clinical Implications for Personalized Treatment. Cell, 187(7), 1617–1635. DOI: 10.1016/j.cell.2024.02.041.https://doi.org/10.1016/j.cell.2024.02.041
  4. Basheeruddin, M., Qausain, S., Anjankar, A., & Khan, F. I. (2026). Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer. Oncology Reviews, 20, 1809836. DOI: 10.3389/or.2026.1809836.https://doi.org/10.3389/or.2026.1809836
  5. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry, 158, 116813 (2023). DOI: 10.1016/j.trac.2022.116813.https://doi.org/10.1016/j.trac.2022.116813
  6. Pencis. (n.d.). International Research Awards on Oncology and Cancer Research. Pencis.https://oncology.pencis.com/

Safeena Kulsum | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Safeena Kulsum
Narayana Hrudayalaya Ltd, India

Safeena Kulsum
Affiliation Narayana Hrudayalaya Ltd
Country India
Scopus ID 57190759680
Documents 6
Citations 173
h-index 4
Subject Area Cancer Biomarkers
Event International Research Awards on, Oncology and Cancer Research

Safeena Kulsum is a researcher affiliated with Narayana Hrudayalaya Ltd in India, with a documented research profile indexed in Scopus under Author ID 57190759680. The supplied profile records six documents, 173 citations, and an h-index of 4, providing a bibliometric basis for describing her scholarly activity. Her stated subject area is Cancer Biomarkers, a field concerned with measurable biological characteristics that can support the understanding and management of disease. Biomarkers may include molecules or molecular signatures detected in tissues, blood, or other biological materials and can contribute to diagnostic, prognostic, and therapeutic decision-making.[1]

Abstract

The Innovative Research Award profile recognizes the documented academic record of Safeena Kulsum in the area of Cancer Biomarkers. The available bibliometric information identifies Narayana Hrudayalaya Ltd as her institutional affiliation and records six Scopus-indexed documents. The supplied metrics further indicate 173 citations and an h-index of 4, which together provide measurable indicators of scholarly visibility within the indexed research record. These indicators are presented descriptively and should be interpreted in relation to publication age, field-specific citation practices, authorship, and database coverage.[2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Molecular Biomarkers
  • Precision Oncology
  • Liquid Biopsy
  • Tumour Biology
  • Cancer Research

Introduction

Cancer biomarkers occupy an important position at the interface of molecular biology, pathology, translational research, and clinical oncology. A biomarker can provide information about a biological process, disease state, treatment response, or other clinically relevant characteristic. The National Cancer Institute notes that biomarkers may be used in understanding disease and evaluating how the body responds to treatment.[1] Their interpretation therefore depends on both biological validity and the context in which testing is performed.

Research Profile

The supplied Scopus record associates Safeena Kulsum with six documents and 173 citations, producing a reported h-index of 4. These metrics offer a concise representation of the indexed publication and citation record available through the supplied author profile. Citation-based indicators are useful for describing research visibility, but they do not independently measure methodological quality, clinical significance, originality, or the practical influence of individual studies. Accordingly, the metrics are best considered alongside publication content and disciplinary context.[2]

Research Contributions

Within the stated field, research contributions may be considered through the development, evaluation, or application of biomarkers that improve understanding of cancer biology. Biomarker investigations can address molecular alterations associated with tumour development, disease progression, therapeutic response, or recurrence. The literature also demonstrates increasing interest in circulating tumour DNA and other liquid-biopsy analytes as tools for longitudinal molecular assessment. These developments emphasize the importance of robust sampling, reproducible laboratory methods, and appropriate clinical validation.[5]

Publications

The supplied Scopus information reports six indexed documents associated with Author ID 57190759680. Because individual publication titles, journal names, publication years, authorship positions, and article identifiers were not supplied, this page does not infer or fabricate a publication list. The Scopus author profile is provided as the primary external source for reviewing the indexed record. Researchers and award reviewers can use that profile to verify individual documents and associated bibliometric information.

Research Impact

The reported citation count of 173 and h-index of 4 indicate that the supplied Scopus record has received measurable scholarly attention. Citation counts can reflect the use of published findings by subsequent researchers, although their interpretation varies considerably between disciplines and publication periods. In cancer research, highly active fields can exhibit different citation patterns from specialized clinical or laboratory areas. Consequently, bibliometric indicators should be interpreted as descriptive evidence rather than as a standalone assessment of research quality.

Award Suitability

The documented research profile is relevant to an academic recognition framework focused on oncology and cancer research because the stated subject area is Cancer Biomarkers. The combination of a defined institutional affiliation, six indexed documents, 173 citations, and an h-index of 4 provides objective bibliometric information for consideration. Award assessment should nevertheless incorporate article-level evidence, research originality, methodological contribution, authorship role, and relevance to the award criteria. These factors help distinguish quantitative visibility from substantive scientific contribution.

Conclusion

Safeena Kulsum is presented here as a researcher affiliated with Narayana Hrudayalaya Ltd, India, with a stated specialization in Cancer Biomarkers. The supplied Scopus record reports six documents, 173 citations, and an h-index of 4 under Author ID 57190759680. These indicators establish a concise bibliometric profile that can support academic recognition while remaining subject to database coverage and periodic updates. More detailed evaluation would require examination of the underlying publications and verified research contributions.

References

    1. National Cancer Institute. (n.d.). Biomarker. NCI Dictionary of Cancer Terms.
      https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
    2. Elsevier. (n.d.). Scopus author details: Safeena Kulsum, Author ID 57190759680. Scopus.
      https://www.scopus.com/pages/authors/57190759680
    3. Valpione, S., Clipson, A., Rothwell, D. G., Dive, C., & Mouliere, F. (2026). Advancing the applications of liquid biopsies in oncology. Nature Reviews Genetics.
      https://doi.org/10.1038/s41576-026-00974-y
    4. Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10, 472–484.
      https://doi.org/10.1038/nrclinonc.2013.110
    5. Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 14, 531–548.
      https://doi.org/10.1038/nrclinonc.2017.14

Cancer Diagnostics and Staging

Published on by Oncology

Cancer Diagnostics and Staging

Introduction: Cancer Diagnostics and Staging play a pivotal role in the timely detection and management of cancer, a disease that continues to be a global health challenge. These critical processes involve the identification of cancerous cells, determining their extent and spread within the body, and providing valuable insights for treatment planning.

Subtopics in Cancer Diagnostics and Staging:

Imaging Techniques:

Explore the use of advanced imaging modalities such as MRI, CT scans, PET scans, and ultrasound in cancer diagnosis and staging.

Biopsy Procedures:

Delve into the various biopsy methods, including fine-needle aspiration, core needle biopsy, and surgical biopsy, used to obtain tissue samples for cancer diagnosis.

Molecular and Genetic Markers:

Discuss the significance of genetic and molecular markers like DNA mutations and biomarkers in identifying cancer types and predicting prognosis.

Liquid Biopsies:

Examine the emerging field of liquid biopsies, which utilize blood samples to detect circulating tumor cells and cell-free DNA for early cancer diagnosis.

TNM Staging System:

Explain the TNM (Tumor, Node, Metastasis) system, a widely accepted method for staging cancers, and its role in determining cancer progression.

These subtopics provide a glimpse into the multifaceted field of Cancer Diagnostics and Staging, which combines medical imaging, laboratory techniques, and clinical assessment to improve the outcomes of cancer patients.